Sanofi Operating Income 2012-2026 | SNY
Sanofi annual/quarterly operating income history and growth rate from 2012 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Sanofi operating income for the quarter ending March 31, 2026 was $2.441B, a 0.07% decline year-over-year.
- Sanofi operating income for the twelve months ending March 31, 2026 was $9.829B, a 7.66% increase year-over-year.
- Sanofi annual operating income for 2025 was $9.831B, a 19.6% increase from 2024.
- Sanofi annual operating income for 2024 was $8.22B, a 14.32% decline from 2023.
- Sanofi annual operating income for 2023 was $9.594B, a 10.51% decline from 2022.
|
Sanofi Annual Operating Income (Millions of US $) |
|
|---|---|
| 2025 | $9,831 |
| 2024 | $8,220 |
| 2023 | $9,594 |
| 2022 | $10,720 |
| 2021 | $9,846 |
| 2020 | $16,389 |
| 2019 | $7,270 |
| 2018 | $6,232 |
| 2017 | $7,070 |
| 2016 | $7,592 |
| 2015 | $7,038 |
| 2014 | $8,534 |
| 2013 | $8,208 |
| 2012 | $8,547 |
| 2011 | $10,445 |
|
Sanofi Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2026-03-31 | $2,441 |
| 2025-12-31 | $1,125 |
| 2025-09-30 | $4,321 |
| 2025-06-30 | $1,941 |
| 2025-03-31 | $2,443 |
| 2024-12-31 | $1,054 |
| 2024-09-30 | $4,204 |
| 2024-06-30 | $1,429 |
| 2024-03-31 | $1,533 |
| 2023-12-31 | $1,376 |
| 2023-09-30 | $3,502 |
| 2023-06-30 | $2,039 |
| 2023-03-31 | $2,676 |
| 2022-12-31 | $2,087 |
| 2022-09-30 | $4,309 |
| 2022-06-30 | $1,634 |
| 2022-03-31 | $2,691 |
| 2021-09-30 | $3,580 |
| 2021-06-30 | |
| 2021-03-31 | $2,527 |
| 2020-09-30 | $2,927 |
| 2020-03-31 | $2,338 |
| 2019-09-30 | $2,516 |
| 2019-03-31 | $1,538 |
| 2018-03-31 | $1,549 |
| 2017-12-31 | $1,188 |
| 2017-09-30 | $2,434 |
| 2017-06-30 | $1,596 |
| 2017-03-31 | $1,851 |
| 2016-12-31 | $1,842 |
| 2016-09-30 | $2,722 |
| 2016-06-30 | $1,724 |
| 2016-03-31 | $1,305 |
| 2015-09-30 | $2,308 |
| 2015-06-30 | $2,131 |
| 2014-06-30 | $1,977 |
| 2013-06-30 | $1,545 |
| 2012-06-30 | $2,183 |
| 2012-03-31 | $2,582 |
| 2011-12-31 | $2,047 |
| 2011-09-30 | $2,184 |
| 2011-06-30 | $1,596 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |